Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Atallah
E
E
Nussenzveig
R
R
Yin
C C
CC
Bueso-Ramos
C
C
Tam
C
C
Manshouri
T
T
Pierce
S
S
Kantarjian
H
H
Verstovsek
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000753:Anemia, Refractory / Q000145:classification / Q000201:enzymology / Q000235:genetics*; D000756:Anemia, Sideroblastic / Q000145:classification / Q000201:enzymology / Q000235:genetics*; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000201:enzymology / Q000235:genetics*; D009196:Myeloproliferative Disorders / Q000145:classification / Q000201:enzymology / Q000235:genetics*; D017354:Point Mutation / Q000235:genetics*; D011379:Prognosis; D015996:Survival Rate; D013922:Thrombocytosis / Q000145:classification / Q000201:enzymology / Q000235:genetics*; D014944:World Health Organization
C507924:JAK2 protein, human; D053614:Janus Kinase 2